The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an …
Enabling better access to kidney disease trials
March is National Kidney Month, and we at Labcorp are committed to improving the renal health of patients worldwide. The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the …
Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America
In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials. We recently asked Nicolas Kirchuk (NK), CEO and co-founder of Biomakers, and Isagani Chico (IC), MD, VP, global …
Delivering solutions to the next generation of cardiovascular medicines
JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning February is American Heart Month, and we at Labcorp are dedicated to improve the cardiovascular health of patients worldwide, as part of Labcorp’s mission to improve health and improve lives. This …
Improving access to rare disease trials by incorporating DCT elements
Welcome to the February 2023 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. With Rare Disease Day coming soon on February 28, we are going to focus on how patients, sites and investigators can benefit by improving the design and execution of rare disease trials. What is Rare Disease Day? …
4 emerging trends to watch in immunotherapy clinical trials
Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies …
How patient-centricity embeds value and stability in LTFU studies
Phase I-III randomized controlled trials alone are not generating enough data to extrapolate conclusions and theories about therapeutics to the global population. Not all drugs demonstrate the same efficacy in the real world as shown in the clinical trials. Because of this, we are seeing a rise in long-term follow-up …
snapClinical® team launches eSource module to revolutionize at-home care for Labcorp Drug Development Mobile Clinical Services
This is a special edition of the Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical. This module represents a cross-functional effort to develop a …
Labcorp to open new kit production innovation base in Suzhou, China
In late July, Labcorp joined the signing ceremony of its kit production innovation base project in Suzhou New District, China. The event was held and organized by the Suzhou New District government and saw attendance from city leadership officials, including Deputy Mayor of Suzhou city, Mr. Xiaodong Tang. The Kit …
Labcorp DCT representation at ARCS, Medidata NEXT, DIA and more – July 2022
Welcome to the July 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. This month, we are going to review our recent presence at several important industry events and provide you with links to a new case study and a just-released video about our snapClinical® technology platform. It has been …